Two cycles of dual neoadjuvant immunotherapy (nivolumab/ipilimumab or nivolumab/relatlimab) induced high pathological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback